This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Eli Lilly and Company. Active years: 2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018
Title: Sudhakar Reddy Chintharlapalli: Innovator in Chemokine Antibodies
Introduction
Sudhakar Reddy Chintharlapalli is a notable inventor based in Zionsville, IN (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies that target specific chemokines. His work has implications for treating various inflammatory and autoimmune diseases, as well as certain types of cancer.
Latest Patents
Chintharlapalli holds a patent for Pan-ELR+ CXC chemokine antibodies. This invention provides antibodies that specifically bind to seven human ELR+ CXC chemokines. The antibodies are particularly useful in treating inflammatory bowel disease (IBD), plaque psoriasis, palmoplantar pustulosis, and cancers such as renal and ovarian cancer. He has 1 patent to his name.
Career Highlights
Chintharlapalli is currently employed at Eli Lilly and Company, a leading global pharmaceutical company. His role involves research and development in the field of therapeutic antibodies, contributing to innovative solutions for complex health issues.
Collaborations
He has collaborated with notable colleagues, including Catherine Brautigam Beidler and Kristine Kay Kikly, who share a commitment to advancing medical science through innovative research.
Conclusion
Sudhakar Reddy Chintharlapalli's work in chemokine antibodies exemplifies the impact of innovation in biotechnology. His contributions are paving the way for new treatments for serious health conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile